Single centre retrospective review of outcome of <scp> <sup>177</sup> Lu‐DOTATATE </scp> peptide receptor radionuclide therapy in the treatment of progressive metastatic neuroendocrine tumours: Survival, toxicity, and prognostic factors-Reference-Cited by-同舟云学术

Single centre retrospective review of outcome of ¹⁷⁷ Lu‐DOTATATE peptide receptor radionuclide therapy in the treatment of progressive metastatic neuroendocrine tumours: Survival, toxicity, and prognostic factors

Published:2022-11 Issue:11 Volume:34 Page:
ISSN:0953-8194
Container-title:Journal of Neuroendocrinology
language:en
Short-container-title:J Neuroendocrinology

Author:

Alsadik Shahad¹^ORCID,Gnanasegaran Gopinath²,Chen Luohai³,Quigley Ann‐Marie²,Mandair Dalvinder⁴,Toumpanakis Christos⁴,Caplin Martyn⁴,Navalkissoor Shaunak²^ORCID

Affiliation:

1. Department of Nuclear Medicine Royal Free Hospital London UK

2. Department of Nuclear Medicine Royal Free London NHS foundation Trust London UK

3. Royal Free London NHS Foundation Trust; Department of Gastroenterology London, United Kingdom. The First Affiliated Hospital, Sun Yat‐sen University Guangzhou China

4. Neuroendocrine Unit Royal Free London NHS foundation Trust London UK

Publisher

Wiley

Subject

Cellular and Molecular Neuroscience,Endocrine and Autonomic Systems,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jne.13210

Reference34 articles.

1. Surgery on neuroendocrine tumours

2. Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

3. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

4. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

5. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-cirrhotic hyperammonaemic encephalopathy secondary to metastatic pancreatic neuroendocrine tumour treated with peptide receptor radio nucleotide therapy and transarterial chemoembolisation;BMJ Case Reports;2024-01

2. Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles;European Journal of Nuclear Medicine and Molecular Imaging;2023-12-02

3. Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single‐institution experience and review of the literature;Journal of Neuroendocrinology;2023-11-08

4. Multiple drug;Reactions Weekly;2023-07-22

5. Safety and Efficacy of 177Lu-DOTATATE in Neuroendocrine Tumor Patients With Extensive Bone Disease;Clinical Nuclear Medicine;2023-05-11